@article{garcia-gomez_lipoprotein_2017,
	title = {Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: {Results} from the {CARdiovascular} in {rheuMAtology} study project},
	volume = {11},
	issn = {1933-2874},
	shorttitle = {Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy},
	doi = {10.1016/j.jacl.2017.02.018},
	abstract = {BACKGROUND: Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved.
OBJECTIVE: The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics.
METHODS: Baseline analysis of the CARdiovascular in rheuMAtology project, a 10-year prospective study, evaluating the risk of cardiovascular events in RA and other forms of inflammatory arthritis. RA patients were classified according to treatment: no biologic, anti-tumor necrosis factor, anti-interleukin-6 receptor tocilizumab (TCZ), and other biologic (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was BT. The model was adjusted for confounding factors.
RESULTS: Seven hundred and seventy-five RA patients were analyzed. Plasma concentrations of total cholesterol and triglyceride were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index between TCZ-treated patients and patients without BT was found. After adjusting for confounding factors, patients with BT had lower concentrations of Lp(a) than those without BT; however, only TCZ-treated patients achieved statistically significant differences (β: -0.303, 95\% confidence interval: -0.558 to -0.047; P = .02).
CONCLUSIONS: RA patients treated with TCZ show lower plasma concentrations of Lp(a) compared with patients without BT.},
	language = {eng},
	number = {3},
	journal = {Journal of Clinical Lipidology},
	author = {García-Gómez, Carmen and Martín-Martínez, Maria A. and Castañeda, Santos and Sanchez-Alonso, Fernando and Uriarte-Ecenarro, Miren and González-Juanatey, Carlos and Romera-Baures, Montserrat and Santos-Rey, José and Pinto-Tasende, José Antonio and Quesada-Masachs, Estefanía and Tornero-Molina, Jesús and Martínez-González, Olga and Cobo-Ibáñez, Tatiana and Chamizo-Carmona, Eugenio and Manrique-Arija, Sara and Fábregas-Canales, Dolores and Díaz-González, Federico and Llorca, Javier and González-Gay, Miguel A. and {CARMA Project Collaborative Group}},
	year = {2017},
	pmid = {28476652},
	keywords = {Article, Biologics, Cardiovascular disease, Lipoprotein(a), Reumatologia, Rheumatoid arthritis, Tocilizumab},
	pages = {749--756.e3},
}

{"_id":"uyWGSfX34pzZHTrPe","bibbaseid":"garcagmez-martnmartnez-castaeda-sanchezalonso-uriarteecenarro-gonzlezjuanatey-romerabaures-santosrey-etal-lipoproteinaconcentrationsinrheumatoidarthritisonbiologictherapyresultsfromthecardiovascularinrheumatologystudyproject-2017","downloads":0,"creationDate":"2018-10-11T03:50:31.163Z","title":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project","author_short":["García-Gómez, C.","Martín-Martínez, M. A.","Castañeda, S.","Sanchez-Alonso, F.","Uriarte-Ecenarro, M.","González-Juanatey, C.","Romera-Baures, M.","Santos-Rey, J.","Pinto-Tasende, J. A.","Quesada-Masachs, E.","Tornero-Molina, J.","Martínez-González, O.","Cobo-Ibáñez, T.","Chamizo-Carmona, E.","Manrique-Arija, S.","Fábregas-Canales, D.","Díaz-González, F.","Llorca, J.","González-Gay, M. A.","CARMA Project Collaborative Group"],"year":2017,"bibtype":"article","biburl":"https://bibbase.org/zotero/Bibliotecacst","bibdata":{"bibtype":"article","type":"article","title":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project","volume":"11","issn":"1933-2874","shorttitle":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy","doi":"10.1016/j.jacl.2017.02.018","abstract":"BACKGROUND: Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved. OBJECTIVE: The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics. METHODS: Baseline analysis of the CARdiovascular in rheuMAtology project, a 10-year prospective study, evaluating the risk of cardiovascular events in RA and other forms of inflammatory arthritis. RA patients were classified according to treatment: no biologic, anti-tumor necrosis factor, anti-interleukin-6 receptor tocilizumab (TCZ), and other biologic (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was BT. The model was adjusted for confounding factors. RESULTS: Seven hundred and seventy-five RA patients were analyzed. Plasma concentrations of total cholesterol and triglyceride were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index between TCZ-treated patients and patients without BT was found. After adjusting for confounding factors, patients with BT had lower concentrations of Lp(a) than those without BT; however, only TCZ-treated patients achieved statistically significant differences (β: -0.303, 95% confidence interval: -0.558 to -0.047; P = .02). CONCLUSIONS: RA patients treated with TCZ show lower plasma concentrations of Lp(a) compared with patients without BT.","language":"eng","number":"3","journal":"Journal of Clinical Lipidology","author":[{"propositions":[],"lastnames":["García-Gómez"],"firstnames":["Carmen"],"suffixes":[]},{"propositions":[],"lastnames":["Martín-Martínez"],"firstnames":["Maria","A."],"suffixes":[]},{"propositions":[],"lastnames":["Castañeda"],"firstnames":["Santos"],"suffixes":[]},{"propositions":[],"lastnames":["Sanchez-Alonso"],"firstnames":["Fernando"],"suffixes":[]},{"propositions":[],"lastnames":["Uriarte-Ecenarro"],"firstnames":["Miren"],"suffixes":[]},{"propositions":[],"lastnames":["González-Juanatey"],"firstnames":["Carlos"],"suffixes":[]},{"propositions":[],"lastnames":["Romera-Baures"],"firstnames":["Montserrat"],"suffixes":[]},{"propositions":[],"lastnames":["Santos-Rey"],"firstnames":["José"],"suffixes":[]},{"propositions":[],"lastnames":["Pinto-Tasende"],"firstnames":["José","Antonio"],"suffixes":[]},{"propositions":[],"lastnames":["Quesada-Masachs"],"firstnames":["Estefanía"],"suffixes":[]},{"propositions":[],"lastnames":["Tornero-Molina"],"firstnames":["Jesús"],"suffixes":[]},{"propositions":[],"lastnames":["Martínez-González"],"firstnames":["Olga"],"suffixes":[]},{"propositions":[],"lastnames":["Cobo-Ibáñez"],"firstnames":["Tatiana"],"suffixes":[]},{"propositions":[],"lastnames":["Chamizo-Carmona"],"firstnames":["Eugenio"],"suffixes":[]},{"propositions":[],"lastnames":["Manrique-Arija"],"firstnames":["Sara"],"suffixes":[]},{"propositions":[],"lastnames":["Fábregas-Canales"],"firstnames":["Dolores"],"suffixes":[]},{"propositions":[],"lastnames":["Díaz-González"],"firstnames":["Federico"],"suffixes":[]},{"propositions":[],"lastnames":["Llorca"],"firstnames":["Javier"],"suffixes":[]},{"propositions":[],"lastnames":["González-Gay"],"firstnames":["Miguel","A."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["CARMA Project Collaborative Group"],"suffixes":[]}],"year":"2017","pmid":"28476652","keywords":"Article, Biologics, Cardiovascular disease, Lipoprotein(a), Reumatologia, Rheumatoid arthritis, Tocilizumab","pages":"749–756.e3","bibtex":"@article{garcia-gomez_lipoprotein_2017,\n\ttitle = {Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: {Results} from the {CARdiovascular} in {rheuMAtology} study project},\n\tvolume = {11},\n\tissn = {1933-2874},\n\tshorttitle = {Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy},\n\tdoi = {10.1016/j.jacl.2017.02.018},\n\tabstract = {BACKGROUND: Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved.\nOBJECTIVE: The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics.\nMETHODS: Baseline analysis of the CARdiovascular in rheuMAtology project, a 10-year prospective study, evaluating the risk of cardiovascular events in RA and other forms of inflammatory arthritis. RA patients were classified according to treatment: no biologic, anti-tumor necrosis factor, anti-interleukin-6 receptor tocilizumab (TCZ), and other biologic (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was BT. The model was adjusted for confounding factors.\nRESULTS: Seven hundred and seventy-five RA patients were analyzed. Plasma concentrations of total cholesterol and triglyceride were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index between TCZ-treated patients and patients without BT was found. After adjusting for confounding factors, patients with BT had lower concentrations of Lp(a) than those without BT; however, only TCZ-treated patients achieved statistically significant differences (β: -0.303, 95\\% confidence interval: -0.558 to -0.047; P = .02).\nCONCLUSIONS: RA patients treated with TCZ show lower plasma concentrations of Lp(a) compared with patients without BT.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Journal of Clinical Lipidology},\n\tauthor = {García-Gómez, Carmen and Martín-Martínez, Maria A. and Castañeda, Santos and Sanchez-Alonso, Fernando and Uriarte-Ecenarro, Miren and González-Juanatey, Carlos and Romera-Baures, Montserrat and Santos-Rey, José and Pinto-Tasende, José Antonio and Quesada-Masachs, Estefanía and Tornero-Molina, Jesús and Martínez-González, Olga and Cobo-Ibáñez, Tatiana and Chamizo-Carmona, Eugenio and Manrique-Arija, Sara and Fábregas-Canales, Dolores and Díaz-González, Federico and Llorca, Javier and González-Gay, Miguel A. and {CARMA Project Collaborative Group}},\n\tyear = {2017},\n\tpmid = {28476652},\n\tkeywords = {Article, Biologics, Cardiovascular disease, Lipoprotein(a), Reumatologia, Rheumatoid arthritis, Tocilizumab},\n\tpages = {749--756.e3},\n}\n\n","author_short":["García-Gómez, C.","Martín-Martínez, M. A.","Castañeda, S.","Sanchez-Alonso, F.","Uriarte-Ecenarro, M.","González-Juanatey, C.","Romera-Baures, M.","Santos-Rey, J.","Pinto-Tasende, J. A.","Quesada-Masachs, E.","Tornero-Molina, J.","Martínez-González, O.","Cobo-Ibáñez, T.","Chamizo-Carmona, E.","Manrique-Arija, S.","Fábregas-Canales, D.","Díaz-González, F.","Llorca, J.","González-Gay, M. A.","CARMA Project Collaborative Group"],"key":"garcia-gomez_lipoprotein_2017","id":"garcia-gomez_lipoprotein_2017","bibbaseid":"garcagmez-martnmartnez-castaeda-sanchezalonso-uriarteecenarro-gonzlezjuanatey-romerabaures-santosrey-etal-lipoproteinaconcentrationsinrheumatoidarthritisonbiologictherapyresultsfromthecardiovascularinrheumatologystudyproject-2017","role":"author","urls":{},"keyword":["Article","Biologics","Cardiovascular disease","Lipoprotein(a)","Reumatologia","Rheumatoid arthritis","Tocilizumab"],"downloads":0,"html":"","metadata":{"authorlinks":{}}},"search_terms":["lipoprotein","concentrations","rheumatoid","arthritis","biologic","therapy","results","cardiovascular","rheumatology","study","project","garcía-gómez","martín-martínez","castañeda","sanchez-alonso","uriarte-ecenarro","gonzález-juanatey","romera-baures","santos-rey","pinto-tasende","quesada-masachs","tornero-molina","martínez-gonzález","cobo-ibáñez","chamizo-carmona","manrique-arija","fábregas-canales","díaz-gonzález","llorca","gonzález-gay","carma project collaborative group"],"keywords":["article","biologics","cardiovascular disease","lipoprotein(a)","reumatologia","rheumatoid arthritis","tocilizumab"],"authorIDs":[],"dataSources":["TR9pX4mH5rDPr29Zo"]}